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Among proteins involved in neurological disease ion channels are amenable to the most 
detailed characterisation: patch-clamp methods allow the opening and closing of individual 
channels to be documented at millisecond resolution in response to precisely delivered 
stimuli (whether electrical or pharmacological). In theory, therefore, inherited disorders of ion 
channels should be ideal candidates to link the functional consequences of individual 
mutations at the molecular level to their clinical manifestations. Disappointingly, it has been 
difficult to ‘explain’ the phenotype of many CNS channelopathies: even where disease-
associated mutations exert robust effects on ion channel properties studied in vitro, a full 
account of the occurrence of hemiplegic migraine, seizures, ataxia or paroxysmal 
dyskinesias remains frustratingly out of reach. More success has been encountered in the 
muscle channelopathies: myotonic discharges are explained by disruption of the normal 
membrane-potential stabilising function of mutated chloride channels, or gain-of-function 
mutations of sodium channels. And if sufficiently severe, impaired inactivation of sodium 
channels predisposes to persistent depolarisation and inexcitability, accounting for attacks of 
periodic paralysis. Nevertheless, even among the muscle channelopathies many puzzles 
remain, not least how mutations that affect voltage-sensing amino acids of sodium or 
calcium channels lead to hypokalaemic periodic paralysis. In contrast to the patchy success 
in explaining genotype-phenotype correlations in most CNS and muscle channelopathies, 
those caused by mutations of the peripheral nerve sodium channel NaV1.7 are showing a 
remarkable degree of consistency, as illustrated by the elegant study of Han and co-workers 
in this issue (Han et al., 2009). 
 
NaV1.7, encoded by the gene SCN9A, is expressed in dorsal root ganglion and sympathetic 
ganglion neurons. Although allocating distinct classes of afferent fibres to different sensory 
roles remains problematic, the experiments of nature represented by human SCN9A 
mutations have provided persuasive evidence that NaV1.7 is important for nociception. 
Three distinct phenotypes have emerged in recent years, with – so far – a striking 
correspondence with the respective biophysical derangement. Primary erythermalgia 
(sometimes also known as erythromelalgia) is characterised by burning pain in the periphery 
exacerbated by high temperatures and associated with redness and oedema of extremities. 
Underlying mutations, which are typically dominantly inherited, lower the voltage at which 
channels activate, and therefore act through a gain of function. A second condition, 
paroxysmal extreme pain disorder (PEPD), is also dominantly inherited, but is characterised 
instead by episodic proximal pain, most prominent in a sub-mandibular, ocular or perineal 
distribution (Fertleman et al., 2007). Indeed, the alternative term familial rectal pain 
syndrome draws attention to the severe attacks that often present in early childhood and can 
lead to secondary constipation. The SCN9A mutations in PEPD also cause a gain in NaV1.7 
function, although through impaired inactivation rather than because of a shift in the 
activation threshold. Although these are distinct disorders, Estacion et al. (2008) recently 
reported overlapping clinical features in a patient with a mutation that both lowered the 
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threshold of activation and impaired inactivation. The final disorder linked to SCN9A is 
congenital indifference to pain. This rare recessive disorder, which has so far only been 
identified in a few consanguineous families, is caused by complete absence of functional 
Nav1.7 channels and results in total loss of sensitivity to noxious stimuli. Thus a remarkably 
consistent genotype-phenotype relation is emerging. A lowered voltage threshold for 
activation presumably leads to spontaneous firing of distal pain fibres, impaired inactivation 
causes paroxysms of severe pain, and absence of the channel eliminates nociception 
altogether. 
 
The second type of genotype-phenotype relationship, the one Han et al. explore here, is 
more subtle. That is the link between the severity of the functional change measured in 
heterologous expression, and the severity of the clinical manifestation, with the age of onset 
of symptoms as a surrogate marker. Han et al. describe a patient whose symptoms of 
primary erythermalgia only came on in mid teens, unlike most patients who present in the 
first decade. The novel mutation, which changes a glutamine residue at position 10 to 
arginine, is associated with the smallest shift yet reported in the voltage dependence of 
activation (-5.3 mV). Indeed, this and the I136V mutation reported and studied by Lee et al. 
(2007) and Cheng et al. (2008) stand out in that both are associated with a shift less than 6 
mV and relatively late onset of symptoms (Table 1).  
 
Demonstrating altered biophysical properties in a simple heterologous expression system is 
however limited in its power to explain the occurrence of symptoms, which are presumably 
due to excessive firing of nociceptors. NaV1.7 is especially suited to amplifying small and 
slow depolarising stimuli because, unlike many other sodium channels, it undergoes 
relatively little ‘closed state’ inactivation, which represents a tendency for sodium channels to 
become reluctant to open upon slow depolarisation even before they have activated. 
Because mutations associated with erythermalgia are dominantly inherited, over-expression 
in small neurons isolated from rat dorsal root ganglion provides a convenient method to 
examine their effects on firing. Han et al. use this method to show that the new Q10R 
mutation decreases the minimal depolarising current required to obtain action potentials. 
However, this effect is smaller than that of the I848T mutation associated with a larger shift 
in activation and earlier onset of symptoms.  
 
Where next? As further spontaneously occurring mutations are identified, it will be important 
to ask whether the correlation between the degree of alteration in biophysical parameters 
and phenotypic severity and age of onset holds up. A more daunting challenge is however to 
understand why mutations that lower the activation threshold and inactivation kinetics are 
associated with such strikingly different manifestations. The temperature sensitivity of mutant 
NaV1.7 associated with erythermalgia may provide a clue to why patients often obtain relief 
from deliberate cooling of their extremities. More widely, however, why are so many 
channelopathies characterised by paroxysmal symptoms, given that the gene defect is fixed 
throughout life? Although a positive feedback between muscle depolarisation and 
extracellular potassium accumulation provides a compelling explanation for attacks of 
hyperkalaemic periodic paralysis associated with gain-of-function muscle NaV1.4 mutations, 
the episodic nature of most other channelopathies remains poorly understood. Finally, will 
the biophysical insights lead to new treatments? As it stands, patients with erythermalgia 
gain modest benefit from drugs such as carbamazepine that facilitate sodium channel 
inactivation, although patients with PEPD seem to benefit more. It remains to be determined 
whether other drugs acting on sodium channels through distinct mechanisms, such as the 
new antiepileptic agent lacosamide, offer any benefit. 
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Table 1 Shifts in activation, age of onset and amino acid position in SCN9A/NaV1.7 
 
 mean 
age of 
onset 
V1/2 of activation shift 
in 
V1/2 
  
a.a. 
position Mutant WT Clinical description 
Electrophysiological 
characterisation 
Q10R 14 
-30.0 ± 0.4 
mV -24.7 ± 0.5 mV -5.3 Han et al., (2009) Han et al., (2009) 
I136V 9 to 22 
-28.8 ± 0.5 
mV 
-23.1 ±  0.7 
mV -5.7 Lee et al., (2007) Cheng et al., (2008) 
F216S <10 
-33.2 ± 1.6 
mV -21.5 ± 1.9 mV -11.7 Drenth et al., (2001) Choi et al., (2006) 
S241T <10 
-34.0 ± 1.1 
mV -25.6 ± 0.9 mV -8.4 Drenth et al., (2005) Lampert et al., (2006) 
N395K <10 
-28.0 ± 1.1 
mV -20.3 ± 0.8 mV -7.7 Drenth et al., (2005) Sheets et al., (2007) 
I848T <10 
-38.4 ± 1.0 
mV -24.6 ± 1.1 mV -13.8 Yang et al., (2004) Cummins et al., (2004) 
L858H 4 to 8 
-37.9 ± 0.9 
mV -24.6 ± 1.1 mV -13.3 Yang et al., (2004) Cummins et al., (2004) 
L858F 2 
-37.2 ± 2.1 
mV -28.0 ± 1.8 mV -9.2 Han et al., (2006) Han et al., (2006) 
A863P <5 
-23.6 ± 0.6 
mV -15.9 ± 0.8 mV -7.7 Harty et al., (2006) Harty et al., (2006) 
V872G 5 
-30.1 ± 1.8 
mV 
- 20.8 ± 1.7 
mV -9.3 Choi et al., (2009) Choi et al., (2009) 
F1449V 3 
-22.8 ± 1.3 
mV -15.2 ± 1.3 mV -7.6 Finley et al., (1992) Dib-Hajj et al., (2005) 
A1632E 3* 
-33.3 ± 0.6 
mV -26.2 ± 1.6 mV -7.1 Estacion et al., (2008) Estacion et al., (2008) 
  
*symptoms of paroxysmal extreme 
pain earlier onset   
 
